CAMARGO’S RESPONSE TO COVID-19
Dear Camargo Clients, Partners, and Colleagues,
As we unite in our worldwide efforts to combat the spread of COVID-19, my thoughts turn first to the patients and communities impacted by this devastating pandemic and the heroic healthcare professionals working tirelessly on the front lines.
I also want to acknowledge the monumental impact of scientists and public health experts at institutions like the World Health Organization and the Centers for Disease Control and Prevention. Guidance and information provided by these organizations has been key to shaping response efforts.
As this global situation continues to evolve, Camargo believes that a sharpened focus and reinvigorated passion for developing medicines that address unmet patient needs are essential contributions our industry can make toward addressing the impact of COVID-19.
To that end, I want to share the ways in which Camargo is doing our part to address this novel coronavirus and support our clients as we navigate through these uncertain times together.
Upholding Our Commitment to Client Service Excellence
The health and well-being of our team is central to our ability to deliver client service excellence. To protect our team and minimize transmission of COVID-19, we have closed our office locations indefinitely, halted all company-sponsored travel, and moved to a remote office format. Guidelines and technology including video conferencing are already in place to facilitate this seamless transition.
Our team is dedicated to ensuring that client commitments and project timelines in our control remain unaffected. We expect no disruptions to our workflow for existing projects and are eager to continue speaking with sponsors about how Camargo can advance their development programs.
Supporting Emergency Use Application (EUA) Requests
Camargo is actively supporting clients developing treatments for COVID-19 as they navigate EUA submission. Our team is honored to lend our expertise in EUA submission preparation and related FDA interactions to those at the forefront of combating this disease.
Sponsors who are developing a treatment for COVID-19 can reach out to our team for support with their FDA submission here.
Advancing Development in a Travel-Restricted World
Travel restrictions are beginning to disrupt sponsors’ ability to manage and monitor their nonclinical studies. Through Camargo Research Group, we offer nonclinical and early clinical study management and monitoring solutions. Our Montreal-based teams work primarily with nearby CROs, and this proximity allows us to continue on-site monitoring activities. If we can help you advance your nonclinical program, please reach out here.
While the current environment has naturally impacted our ability to participate in industry events, we greatly value the opportunity to connect with those in our network and will continue to do so via video conferencing and phone calls. You can request a meeting here.
For those we had planned to meet at specific upcoming events, here are our current plans:
• BIO-Europe Spring: Camargo will be using BIO-Europe Spring’s digital platform to attend the conference and engage with our network.
• DCAT: Camargo will be using video conferencing to maintain DCAT meetings, despite cancellation of this event.
Please reach out to your Camargo business contact with any questions or feedback on how we can best support you during this time.
Thank you and stay safe,
Daniel S. Duffy
Chief Executive Officer
Camargo Pharmaceutical Services partners with sponsors to build and execute customized drug development and commercial programs that deliver better outcomes for all stakeholders. We specialize in complex and rare disease programs where no playbook exists. Through a high-science, creatively bold approach, we pioneer new pathways to accelerate pivotal milestones and help deliver hope to more patients.